ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

6,556Medicare Part D Prescriptions Filled, Including Refills

Rank: 1224 out of 3734

$379K Total Retail Price of All Prescriptions

Rank: 1209 out of 3734

325 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 325 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

9% of this provider’s 325 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 5,961 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
SIMVASTATIN 320 298 1 1
AMLODIPINE BESYLATE 228 226 2 5
LEVOTHYROXINE SODIUM 227 191 3 2
LISINOPRIL 220 203 4 3
METFORMIN HCL 194 164 5 8
OMEPRAZOLE 187 168 6 4
FUROSEMIDE 183 182 7 7
SERTRALINE HCL 126 107 8 18
METOPROLOL SUCCINATE 124 120 9 14
ZOLPIDEM TARTRATE 115 100 10 24
HYDROCHLOROTHIAZIDE 111 108 11 9
LISINOPRIL-HYDROCHLOROTHIAZIDE 108 100 12 27
NAMENDA 107 107 13 44
METOPROLOL TARTRATE 106 96 14 6
ATORVASTATIN CALCIUM 101 96 15 11
KLOR-CON M20 78 78 16 48
CITALOPRAM HBR 78 73 16 16
ATENOLOL 78 75 16 13
PRAVASTATIN SODIUM 77 67 19 15
NEXIUM 73 59 20 36
ALLOPURINOL 73 69 20 33
CRESTOR 69 69 22 28
ALENDRONATE SODIUM 66 66 23 26
AZITHROMYCIN 64 54 24 38
GABAPENTIN 62 56 25 17
DIGOXIN 60 60 26 43
LORAZEPAM 59 59 27 210
TAMSULOSIN HCL 58 54 28 29
GLIPIZIDE ER 58 57 28 119
DIOVAN HCT 54 54 30 72
POTASSIUM CHLORIDE 54 53 30 19
HYDROCODONE-ACETAMINOPHEN 54 42 S3 30 12
DONEPEZIL HCL 54 54 30 25
TRAMADOL HCL 53 48 34 20
MIRTAZAPINE 53 53 34 45
POLYETHYLENE GLYCOL 3350 53 52 34 53
OXYCODONE-ACETAMINOPHEN 52 47 S2 37 51
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 7, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.